(Reuters) – Fulcrum Therapeutics said on Thursday its experimental drug to treat a type of genetic muscle disorder failed to meet the main goal in a late-stage study.
Shares of the company slumped over 70% to $2.4 in premarket trading.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Vijay Kishore)
Comments